Our study provides evidence that exposing PR-positive breast cancer cells to progestin, as happens with women taking progestin-containing hormone replacement therapy, could tremendously increase expression of microRNAs in some breast cells that under normal physiological conditions would not express significant levels of these microRNAs, leading to altered expression of targeted genes. The gene discussed is PGR; the disease is breast carcinoma.